TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30962251
Drug: Epidural steroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural steroid injection (ESI) in individuals with intermediate non-immune-mediated HR (n=52)
Study: 30962251
Drug: Epidural steroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural steroid injection (ESI) in individuals with high non-immune-mediated HR (n=24)
Study: 30962251
Drug: Epidural steroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural steroid injection (ESI) in individuals with low immune-mediated HR
Study: 30962251
Drug: Epidural steroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural steroid injection (ESI) in individuals with intermediate immune-mediated HR
Study: 30962251
Drug: Epidural steroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural steroid injection (ESI) in individuals with high immune-mediated HR
Study: 28528859
Drug: Oral Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Cyclosporine A (CyA) at 3 mg/kg divided twice daily for 3 months
Study: 23458037
Drug: Sevoflurane (2%)
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane (2%) and tramadol (2 mg/kg) combination
Study: 18424221
Drug: Dopaminergic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopaminergic treatment in patients with PD
Study: 18424221
Drug: Drug-naïve patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-naïve patients with PD
Study: 3329532
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg terbutaline by metered dose inhaler (MDI)
Study: 3329532
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg terbutaline subcutaneously (SC)
Study: 3329532
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo SC plus 2 mg terbutaline by MDI
Study: 3329532
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg terbutaline SC plus placebo by MDI
Study: 11994056
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam (5 mg)
Study: 11994056
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam (5 mg)
Study: 14676756
Drug: 2 grams
Normalized name: phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 grams of pheneticillin administered orally one hour before surgery
Study: 14676756
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally one hour before surgery
Study: 8864962
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pravastatin and sitostanol ester margarine
Study: 8864962
Drug: Control margarine
Normalized name: MARGARINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control margarine (24 g daily)
Study: 6084139
Drug: Guanabenz (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanabenz (average daily dosage 16 to 31 mg)
Study: 6084139
Drug: Hydrochlorothiazide (HCTZ,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ, average daily dosage 50 to 75 mg)
Study: 30001202
Drug: Adjuvant low-level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant low-level laser therapy
Study: 30001202
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (topical medication and compressive therapy)
Study: 27300579
Drug: Vildagliptin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin (50 mg twice daily = 100 mg/d)
Study: 27300579
Drug: Sitagliptin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (100 mg once daily for diet, 50 mg twice daily for metformin = 100 mg/d)
Study: 16138073
Drug: Amicar (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amicar (100 mg/kg over 15 minutes, maintenance 10 mg/kg per hour until wound closure)
Study: 7540965
Drug: Placebo (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (one matching tablet per day)
Study: 1975851
Drug: Budesonide pressurised
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide pressurised aerosol 400 micrograms twice daily
Study: 762813
Drug: Reserpine (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reserpine (0.125 to 0.250 mg) plus Hydroflumethiazide (50 or 100 mg)
Study: 762813
Drug: Methyldopa (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa (500 to 2,000 mg) plus Hydroflumethiazide (50 or 100 mg)
Study: 762813
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 to 320 mg) plus Hydroflumethiazide (50 or 100 mg)
Study: 29796932
Drug: Low-phytate wholegrain
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-phytate wholegrain bread (200 g/day)
Study: 29796932
Drug: High-phytate wholegrain
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-phytate wholegrain bread (200 g/day)
Study: 23986780
Drug: Tai Chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi plus antihypertensive drugs
Study: 21845243
Drug: MCBS with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCBS with recombinant human platelet‐derived growth factor BB [rhPDGF‐BB; 0.3 mg/mL]
Study: 21845243
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of EMD with bone ceramic
Study: 18663294
Drug: DPOAE Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPOAE Protocol P1 (L(1) = 60, L(2) = 50 dB SPL)
Study: 18663294
Drug: DPOAE Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPOAE Protocol P2 (L(1) = 65, L(2) = 55 dB SPL)
Study: 18663294
Drug: DPOAE Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPOAE Protocol P3 (L(1) = 75, L(2) = 65 dB SPL)
Study: 14681716
Drug: hyperosmolality induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: hyperosmolality induced by fluid restriction and intravenous infusion of hypertonic NaCl (2‐5%, wt/vol) during 17 h
Study: 14681716
Drug: hypo‐osmolality produced
Approvals — FDA: no, EMA: no, PMDA: no
Description: hypo‐osmolality produced by intravenous administration of desmopressin, liberal water drinking and infusion of hypotonic saline (0.4%)
Study: 14681716
Drug: iso‐osmolality study
Approvals — FDA: no, EMA: no, PMDA: no
Description: iso‐osmolality study with oral water intake ad libitum
Study: 9089663
Drug: Botulinum neurotoxin
Normalized name: Botulinum neurotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum neurotoxin type A (BoNt/A) preparation 1 injected into the left foot
Study: 9089663
Drug: Botulinum neurotoxin
Normalized name: Botulinum neurotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum neurotoxin type A (BoNt/A) preparation 2 injected into the right foot
Study: 9089663
Drug: Both preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both preparations (1 and 2)
Study: 7933838
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human IGF-I (rhIGF-I) (100 micrograms/kg body wt subcutaneously twice daily) - short-term treatment (4 days)
Study: 7933838
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human IGF-I (rhIGF-I) (100 micrograms/kg body wt subcutaneously twice daily) - long-term treatment (13-27 days)
Study: 3220789
Drug: Single volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single volume exchange transfusion (ET; 80 ml/kg)
Study: 3220789
Drug: Double volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double volume exchange transfusion (ET; 160 ml/kg)
Study: 1985161
Drug: Long arm
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long arm (5 additional courses with 2 additional drugs; 16 weeks)
Study: 9665188
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment arms (short and long)
Study: 872103
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy and/or immunotherapy
Study: 29065916
Drug: Sertraline starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline starting at 50 mg daily for 1 week, increasing to 100 mg daily for up to 11 weeks (with the option of increasing to 150 mg if required)
Study: 24020866
Drug: Naloxone (3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (3.2 mg/70 kg body weight)
Study: 19701110
Drug: Pemetrexed at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed at 750 mg/m2 every 21 days with weekly cetuximab at 250 mg/m2
Study: 19701110
Drug: Historical controls
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical controls of either single agent
Study: 18000101
Drug: Significant other
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Significant other primes (e.g., mother, roommate)
Study: 12849651
Drug: Glycoprotein IIb/IIIa
Normalized name: GLYCOPROTEIN IIB/IIIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoprotein IIb/IIIa inhibitors with thrombolytic agents
Study: 12849651
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with GP IIb/IIIa inhibitors and thrombolytic agents
Study: 12119202
Drug: Atorvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (40 mg per day)
Study: 21473764
Drug: Inhaled beclometasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclometasone (400 μg per day) with atorvastatin
Study: 10769276
Drug: Ciprofibrate therapy
Normalized name: ciprofibrate
DrugBank: Ciprofibrate (DB09064)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofibrate therapy
Study: 9068936
Drug: Sertraline tablets
Normalized name: sertraline Oral Tablet
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline tablets (morning administration)
Study: 9068936
Drug: Sertraline tablets
Normalized name: sertraline Oral Tablet
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline tablets (evening administration)
Study: 9068936
Drug: Sertraline tablets
Normalized name: sertraline Oral Tablet
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline tablets (with food)
Study: 9068936
Drug: Sertraline tablets
Normalized name: sertraline Oral Tablet
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline tablets (without food)
Study: 25786565
Drug: SRP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP plus 1.2 mg rosuvastatin gel
Study: 21703001
Drug: Patient education
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient education integrated with acupuncture (two parts: self-care education in four weekly 50-minute sessions and eight weekly 50-minute acupuncture sessions)
Study: 16875647
Drug: High-dose methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methylprednisolone (100 mg every 4 hours)
Study: 25667122
Drug: Rocuronium (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium (0.9 mg kg(‐1))
Study: 21908961
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia (SA) with 3 ml of 0.75% ropivacaine
Study: 21908961
Drug: Combined sciatic/lumbar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined sciatic/lumbar plexus nerve block (CSLPB) with 10 ml 0.75% ropivacaine and 10 ml of normal saline (20 ml total)
Study: 14622081
Drug: Fluoxetine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine plus self-exposure (FLU + SE)
Study: 7588456
Drug: Patients receiving
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving long-term anticonvulsant therapy
Study: 2121394
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (buserelin) 100 micrograms
Study: 582772
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg WE 941
Study: 582772
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg WE 941
Study: 582772
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg WE 941
Study: 582772
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg flurazepam
Study: 11525594
Drug: Fresh broccoli
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh broccoli (200 g)
Study: 11525594
Drug: Steamed broccoli
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steamed broccoli (200 g)
Study: 8288160
Drug: Dexfenfluramine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexfenfluramine (15 mg twice daily for 8 days)
Study: 24332524
Drug: Oligofructose-enriched inulin
Normalized name: Inulin
DrugBank: Inulin (DB00638)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oligofructose-enriched inulin (10 g/d)
Study: 24332524
Drug: Maltodextrin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin (10 g/d)
Study: 21877913
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin monotherapy (n=27)
Study: 21877913
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous insulin infusion (CSII) (n=32)
Study: 19164492
Drug: Extended-release bupropion
Normalized name: bupropion Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release bupropion (150-300 mg once daily)
Study: 16389916
Drug: Test drug
Normalized name: URINE TEST DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug
Study: 12362231
Drug: Oral E(2)
Normalized name: Aquasol E Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral E(2) 1 mg (oE(2) group, n = 37)
Study: 12362231
Drug: Oral E(2)
Normalized name: Aquasol E Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral E(2) 1 mg combined with gestodene 25 micro g (oE(2) + G group, n = 33)
Study: 12362231
Drug: Transdermal 17beta‐oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17beta‐oestradiol (E(2)) 50 micro g (tE(2) group, n = 33)
Study: 1309390
Drug: 0.1 ml
Normalized name: ethanol 0.1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml of iodized oil (47 mg of iodine)
Study: 1309390
Drug: 0.25 ml
Normalized name: mineral oil 0.25 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 ml of iodized oil (118 mg of iodine)
Study: 31780001
Drug: Nasal spray
Normalized name: Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray containing IND02 (100 μg/100 μL), twice a day for seven days
Study: 26985911
Drug: Adherent interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adherent interventions to the Clinical Treatment Algorithm (CTA)
Study: 26985911
Drug: Nonadherent interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonadherent interventions to the Clinical Treatment Algorithm (CTA)
Study: 25468575
Drug: Warmed i-gel
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warmed i-gel (42°C for 30 minutes)
Study: 25468575
Drug: Room temperature
Normalized name: ROOM DEODORIZER POWDER MENTOR #3202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room temperature i-gel (approximately 23°C)
Study: 19333160
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral water)
Study: 7038189
Drug: Cefroxadine (CXD)
Normalized name: cefradine
DrugBank: Cefroxadine (DB11367)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefroxadine (CXD) at doses of 5, 10, and 20 mg/kg
Study: 26949924
Drug: Psychoeducation text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducation text focusing on medication
Study: 26949924
Drug: Psychoeducation text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducation text focusing on psychodynamic therapy
Study: 20412274
Drug: Rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 4 mg twice daily for 4 months
Study: 20412274
Drug: Pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30 mg daily for 4 months
Study: 16277141
Drug: Treatment optimism
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment optimism
Study: 28342943
Drug: Antipsychotics for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotics for schizophrenia
Study: 28342943
Drug: Perceived treatability
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceived treatability and belief in effectiveness of treatment for schizophrenia
Study: 28342943
Drug: Perceived treatability
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceived treatability and belief in effectiveness of treatment for depression
Study: 26651484
Drug: Behavior change
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior change strategy consisting of one individual theoretical counseling session plus eight twice-a-week individual theoretical and practical exercise counseling sessions for 3 years.
Study: 26651484
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care including general physician recommendations for daily PA.
Study: 19036671
Drug: Vancomycin 2
Normalized name: vancomycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 2 g/day (1 g intravenously twice daily) and Aztreonam 4 g/day (2 g intravenously twice daily)
Study: 16609033
Drug: High LET
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High LET carbon beam therapy
Study: 8929043
Drug: Ketorolac infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac infusion (150 mg in 60 ml isotonic chlorinated solution at 0.5 ml/h + 4 bolus/h of 0.5 ml)
Study: 8929043
Drug: Morphine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine infusion (60 ml in 60 ml isotonic chlorinated solution at the same rate)
Study: 8929043
Drug: Placebo (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (60 ml isotonic chlorinated solution + Ketorolac intramuscular on demand)
Study: 6375805
Drug: Cicloxolone cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicloxolone cream
Study: 6375805
Drug: Carbenoxolone cream
Normalized name: carbenoxolone
DrugBank: Carbenoxolone (DB02329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenoxolone cream
Study: 30219432
Drug: Psyllium (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium (10 g pre-mixed in cookies twice per day for 12 weeks)
Study: 22500643
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment at Waiyingxiang (LI 20)
Study: 20605871
Drug: CPB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPB with low tidal volume ventilation (3 ml.kg(‐1)) without positive end expiratory pressure (PEEP)
Study: 17433950
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of enalaprilat
Study: 11971197
Drug: New treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: New treatment schedule of melarsoprol (10 daily doses of 2.16 mg/kg)
Study: 11971197
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment protocol of melarsoprol (3 series of 3-4 injections every 24 hours)
Study: 11971197
Drug: New treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: New treatment schedule of melarsoprol
Study: 11971197
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment protocol of melarsoprol
Study: 12914803
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive therapy
Study: 1972434
Drug: Indomethacin (0.1‐0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (0.1‐0.2 mg/kg) administered by rapid injection (30 s)
Study: 1972434
Drug: Indomethacin (0.1‐0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (0.1‐0.2 mg/kg) administered by slow infusion (20‐30 min)
Study: 29127080
Drug: 24 mg
Normalized name: uracil 224 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mg ENDS
Study: 29127080
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg ENDS
Study: 31086287
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg rhCC10
Study: 31086287
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg rhCC10
Study: 10211913
Drug: Zatosetron 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zatosetron 0.2 mg
Study: 10211913
Drug: Zatosetron 1
Normalized name: alosetron 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zatosetron 1 mg
Study: 10211913
Drug: Zatosetron 5
Normalized name: alosetron 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zatosetron 5 mg
Study: 7789938
Drug: McCanse Readiness
Approvals — FDA: no, EMA: no, PMDA: no
Description: McCanse Readiness for Death Instrument (MRDI) administered to terminally-ill individuals
Study: 7789938
Drug: McCanse Readiness
Approvals — FDA: no, EMA: no, PMDA: no
Description: McCanse Readiness for Death Instrument (MRDI) administered to cardiac-impaired individuals (control group)
Study: 354312
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of calcium per day
Study: 21977379
Drug: Rivastigmine patch
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine patch (9.5 mg/24-h)